Book by Workshops: 20th April 2010 | Meeting: 21st and 22nd April 2010 February 19th Location: Radisson Blu Hotel, Frankfurt, Germany and save up to Advancing E400 Protein Therapeutics Optimising Therapeutic Potential During Research and Development Advancing Protein Therapeutics focuses on overcoming the key Hear 24 world leading protein challenges in optimising therapeutic and drug-like qualities, therapeutic experts and will help you to maximise the commercial potential of your protein therapeutic pipeline. • Dr Graham Molineux, Executive Director, Research, Amgen n Learn the latest techniques for engineering protein therapeutics • Dr Tom Kost, Director, Biological Reagents and Assay to improve PK/PD and immunogenicity, with an overview from Dr Development, GlaxoSmithKline Graham Molineux, Executive Director of Research at Amgen. • Dr Lutz Jermutus, Senior Director, Technology, MedImmune n Get an update on the latest methodologies for expression and • Dr Scott Glaser, Director of Antibody Therapeutics, production of therapeutic proteins with presentations from Dr Biogen Idec Tom Kost, Director of Biological Reagents and Assay Development • Dr Michael Doyle, Group Leader, Protein Therapeutics for GSK and Dr Trevor Wilkinson, Associate Director of Protein Discovery Biochemistry and Biophysics, Bristol-Myers Sciences at MedImmune Squibb Research and Development • Dr Chichi Huang, Research Fellow, Centocor n Dr Michael Doyle, Group Leader of Protein Therapeutics (Johnson & Johnson) Discovery at Bristol-Myers Squibb, outlines the application of a • Dr Andy Nixon, Vice President, Lead Discovery and thermodynamic solubility assay during lead selection Biochemistry, Dyax Corp • Dr Trevor Wilkinson, Associate Director of Protein n Understand how Medimmune are developing novel biologics Sciences, MedImmune to target less accessible cell surface antigens, with a detailed • Prof Arne Skerra, Professor of Biological Chemistry, description from Dr Lutz Jermutus, their Senior Director of Technische Universitat Munchen Technology. • Dr Josi Holz, Chief Medical Officer,Ablynx n Dr Scott Glaser, Director of Antibody Therapeutics at Biogen • Dr Lars Abrahmsen, Chief Scientific Officer,Affibody • Dr Julian Bertschinger, Co-founder and Chief Executive Idec, outlines the very latest developments in the construction of Officer,Covagen bispecific antibodies, including preclinical examples • Dr Arnd Steuernagel, Chief Scientific Officer,ScilProtein n Discover how Centocor (Johnson & Johnson) are using Fc-Fusion • Dr Christian Zahnd, Chief Executive Officer, proteins to enhance therapeutic potential and extend half-life Molecular Partners • Dr Christina Furebring, Vice President Research & Development, Alligator Bioscience • Dr Samantha Cobb, Chief Executive Officer,AdAlta INTERACTIVE WORKSHOPS Tuesday 20th April • Dr Jeffrey Cleland, Chief Executive Officer, Versartis • Dr Kendall Mohler, Senior Vice President, Research & Intellectual Property in Therapeutic Proteins 9.30 - 12.30 Development, Trubion Dr Antonio Maschio, Partner • Dr Nico Mertens, Senior Director of Antibody Engineering, Edwards Angell Palmer & Dodge Innovations LLP Biotecnol • Prof Christian Heinis, Group Head, EPFL Challenges in the Clinical Development 13.30 - 16.30 • Dr Kevin FitzGerald, Chief Executive Officer, of Biological Medicines f-star GmbH Cecil Nick, Vice President (Biotechnology), PAREXEL Consulting • Dr Andreas Hohlbaum, Chief Technology Officer, Pieris AG • Dr Dominik Escher, Managing Director and Vice President Media Partners R&D, ESBATech • Dr Karyn O’Neil, Chief Scientific Officer,Centyrex, Johnson & Johnson Ventures To register: www.protein-therapeutics.com • Email [email protected] Tel +44 (0) 203 141 8700 • Fax +44 (0)20 7222 2685 Workshops: 20th April 2010 | Meeting: 21st and 22nd April 2010 | Location: Radisson Blu Hotel, Frankfurt, Germany Optimising Therapeutic Potential During Research and Development Enhancing Protein Therapeutics to Deliver Business Growth Advancing protein therapeutics through the clinic and into the market is fraught with difficulties. So why make it any tougher? Invaluable feedback on your protein therapeutics The agenda for this meeting has been designed with direct The quality and rate of innovative research and development input from most of the successful innovative companies in the proteins therapeutics sector has increased dramatically in the last few years. As part of the Biorbis mission to developing protein drugs today. Companies like Pfizer, Merck, accelerate progress and encourage dialogue, we encourage MedImmune, Biogen Idec, Amgen, GSK, Johnson & attendees to present a poster. Johnson, Bristol-Myers Squibb and Roche, have all given Presenting a poster is free of charge to all registered delegates. Please note that poster displays may not be used frank and honest assessments of principle challenges facing for sales or marketing purposes, and all poster abstracts are protein therapeutic developers. subject to approval by the conference organisers. Just tick on the booking form or inform us when registering. We’ve collated this information into an agenda, and collected Contact Richard Lumb at [email protected] some of the world’s leading experts in the field, to provide you for more details with valuable knowledge and first-hand experiences that you simply cannot get elsewhere. Who Should Attend Advancing Protein Therapeutics is an elite meeting of Hear the world’s brightest minds talking about: international scientists and research leaders from the major pharmaceutical companies and large, medium and small n Improving the PK/PD characteristics of your protein biotechs. Directors and Heads of Biologics, Protein Engineering, R&D, Chief Executive and Scientific therapeutics, including modulation of half–life and Officers, research leaders and scientists will all benefit matching of pharmacokinetics to clinical requirements. and have the opportunity to debate issues at the cutting edge of the sector. n Enhancing production of proteins for therapeutic application Register now and speak to the most innovative biotechs in the sector and forward-thinking research establishments. Make and for preclinical studies using novel expression the most of opportunities for face-to-face dialogue during systems. our interactive and networking sessions and converse with the other attendees as well as the skilled speaker faculty. Just n Improving the therapeutic effectiveness of protein be ready to talk about your work and don’t forget to bring therapeutics, including efficacy and tissue penetration. plenty of business cards. n Expanding the alternative scaffold portfolio to include completely novel antibody-alternatives. Biorbis in on an unrelenting mission to deliver scientific meetings to the n The very latest developments in advancing multivalent business and research community that will accelerate progress and protein therapeutics towards the clinic ultimately benefit patients. Our focus is on discovering what makes a difference to your n How to design protein therapeutics that target less research or business, and working with you to design highly accessible cell surface antigens relevant, cutting-edge agendas with content delivered by globally recognised experts and leaders in the field. n An interactive panel discussion addressing the future of We create an environment that encourages open dialogue, frank discussion, generation of ideas and exchange of protein therapeutics, including overcoming challenges information that will help to advance medical science and in progressing to the clinic and an assessment of the most improve your research or grow your business. promising alternative scaffolds. www.biorbis.com To register: www.protein-therapeutics.com • Email [email protected] Tel +44 (0) 203 141 8700 • Fax +44 (0)20 7222 2685 Workshops: 20th April 2010 | Meeting: 21st and 22nd April 2010 | Location: Radisson Blu Hotel, Frankfurt, Germany CONFERENCE DAY ONE: 21st April 2010 08.30 Registration, coffee and networking PRODUCING PROTEINS FOR THERAPEUTIC APPLICATION 09.00 Chairman’s Opening Remarks Dr Scott Glaser, Director, Antibody Therapeutics, Biogen Idec 13.45 BacMam Transduction: A Versatile Approach for Protein Expression IMPROVING PHARMACODYNAMICS / n Utilising BacMam viruses for gene delivery and protein PHARMACOKINETICS expression as an alternative to transient transfection n Flexibility of BacMam virus gene delivery system in assay development and potential in protein production for pre- 09.05 KEYNOTE ADDRESS: Engineering Protein Therapeutics to clinical studies. Improve PK/PD and Immunogenicity Dr Tom Kost, Director, Biological Reagents & Assay Development n Evolution of protein therapeutics to enhance pharmacology GlaxoSmithKline profiles n Addressing safety concerns during protein development 14.15 Transient Production of Recombinant Proteins in Dr Graham Molineux, Executive Director, Research, Amgen Inc Mammalian Cells and its Role in Supporting Drug Discovery Programs n Applications of transient mammalian expression systems 09.35 Engineering Kunitz Domains to Extend Plasma Half-Life n Expression of recombinant antigens and antibodies using PEGylation and Protein Fusions n Case studies describing support of Drug Discovery Programs n Overview of the design features of a human Kunitz domain Dr Trevor Wilkinson, Associate Director, Protein Sciences scaffold library MedImmune n Identification of engineered potent and selective serine protease inhibitors using a human Kunitz domain scaffold